Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

Open access
Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., Levy, E. M. · 2011 · Breast Cancer Research and Treatment

Abstract

Triple negative breast cancer (TNBC) patients are not likely to benefit from anti-estrogen or anti-HER2 therapy and this phenotype is associated with a more aggressive clinical course and worse clinical outcome. Taking into account the limited treatment possibilities in TNBC, the aim of the present work was to study a potential therapy based on Cetuximab-mediated immune activity by natural killer (NK) cells. We performed in vitro studies on human breast cancer (BC) cell lines, IIB-BR-G, and the in vivo metastatic variant IIB-BR-G MT. The immunohistochemical analysis showed a TNBC phenotype with high but different levels of EGFR expression on each cell line, measured by flow cytometry. DNA sequencing showed that both cell lines have a mutated K-RAS status, 38 G > A at codon 13. Consequently, Cetuximab did not inhibit cellular proliferation or induce apoptosis. We investigated if Cetuximab could trigger immune mechanisms, and we determined that both cell lines treated with 1 μg/ml Cetuximab were susceptible to antibody dependent cellular cytotoxicity (ADCC), mediated by peripheral blood mononuclear cells (PBMC). At 50:1 effector:target ratio, lytic activity was 34 ± 2% against IIB-BR-G and 27 ± 6% against IIB-BR-G MT cells. PBMC pretreatment with IL-2 allowed reaching 65 ± 3% of Cetuximab-mediated ADCC against IIB-BR-G and 63 ± 6.5% against IIB-BR-G MT. Furthermore, IL-15 pretreatment increased the ADCC up to 71 ± 3% in IIB-BR-G and 79 ± 3.5% in IIB-BR-G MT. We suggest that NK cells are the effectors present in PBMC since they were able to induce ADCC at lower effector:target ratios. Besides, IL-2- and mainly IL-15-induced upregulation of NK activating receptors CD16 and NKG2D and enhanced IFN-γ production. EGFR-expressing TNBC could be killed by Cetuximab-mediated ADCC at clinically achievable concentrations. IL-15 could advantageously replace IL-2 in most of its immunologic activities, stimulating the ability to produce IFN-γ, and paralleling the up-regulation of activating receptors.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10549-011-1360-2

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 2

  1. Tavassoli F, Deville P (2003) World Health Organization: tumours of the breast and female genital organs (2003) (Who/IARC Classifications of Tumours). IARC, Lyon
  2. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937–943 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M.
Affiliations
  • Instituto Alexander Fleming (AR)
  • Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
Corresponding author
Levy, E. M.
Venue
Breast Cancer Research and Treatment
Published
2011-02-10
Volume
130
Issue
2
Pages
465-475
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2081328283
Cited by
51
References
45
Citations by year
2026: 1 · 2024: 3 · 2022: 2 · 2021: 5 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 4 · 2015: 6 · 2014: 2 · 2013: 1 · 2012: 8
FWCI
2.27
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-sa
  • www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
  • CONICET Digital (CONICET) (submittedVersion, cc-by-nc-sa)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
triple-negative breast cancer, cetuximab, antibody-dependent cellular cytotoxicity, IL-15, interleukin-2, natural killer cells, EGFR, KRAS mutation, CD16, NKG2D, interferon-gamma, NK cell activating receptors, metastatic breast cancer, cancer immunotherapy, peripheral blood mononuclear cells
MeSH terms
Cetuximab, Antibodies, Monoclonal, Antineoplastic Agents, Base Sequence, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Interferon-gamma, Interleukin-2, Killer Cells, Natural, Proto-Oncogene Proteins, Receptors, Estrogen, Receptors, Progesterone, Up-Regulation, Proto-Oncogene Proteins p21(ras), Apoptosis, Point Mutation, Receptors, IgG, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Coculture Techniques, Interleukin-15, Cell Line, Tumor, Cell Proliferation, NK Cell Lectin-Like Receptor Subfamily K, GPI-Linked Proteins, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. https://app.cochat.ai/papers/10.1007/s10549-011-1360-2
The paper
Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M. (2011). IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-011-1360-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.